## Abstract Accurate assessment of the causes of death is crucial for a conclusive evaluation of the ongoing prostate cancer screening trials. Here, we report the validity of the official causes of death as compared with an independent expert review in the Finnish prostate cancer screening trial. B
Determining the cause of death in randomized screening trial(s) for prostate cancer
✍ Scribed by H.J. De Koning; J. Blom; J.W. Merkelbach; R. Raaijmakers; H. Verhaegen; P. Van Vliet; V. Nelen; J.W.W. Coebergh; A. Hermans; S. Ciatto; T. MÄKinen
- Book ID
- 110928155
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 154 KB
- Volume
- 92
- Category
- Article
- ISSN
- 1464-4096
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mo
## Background: The 46,193 men aged 45 to 80 years registered in the electoral roll of quebec city and its metropolitan area were randomized in november 1988 between screening and no screening in a study aimed of assessing the impact of prostate cancer screening on cause-specific death. ## Methods: